FT218

Phase 3Small molecule

AAvadel

FT218 is one of 7 small molecule programs targeting Idiopathic Hypersomnia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic HypersomniaActive, not recruiting

Idiopathic HypersomniaPhase 3

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Idiopathic Hypersomnia

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

—2

Romazicon

CConrado Roberto Hoffmann Filho

Approved

—3

Sunosi

AAxsome Therapeutics, Inc.

Phase 2

1 4

Low Sodium Oxybate

SStanford University

Phase 3

2 5

TAK-360

Takeda

Phase 2

2 6

FT218

AAvadel

Phase 3

1 7

ORX750

CCentessa Pharmaceuticals (UK) Limited

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Narcolepsy2 trials

Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

Completed·AAvadel·Phase 3·NCT02720744·212 enrolled

An Open Label Study of FT218 in Subjects With Narcolepsy

Completed·AAvadel·Phase 3·NCT04451668·184 enrolled

Idiopathic Hypersomnia1 trial

Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)

Active, not recruiting·AAvadel·Phase 3·NCT06525077·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for FT218. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FT218 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FT218. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Avadel company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAvadel

FT218

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Narcolepsy2 trials

Idiopathic Hypersomnia1 trial

References

Drug Info

Quick Facts

Related News